William Blair Analysts Raise Earnings Estimates for CVRx, Inc. (NASDAQ:CVRX)

CVRx, Inc. (NASDAQ:CVRX) – Equities research analysts at William Blair boosted their Q1 2024 earnings per share (EPS) estimates for CVRx in a research note issued to investors on Tuesday, November 14th. William Blair analyst M. Kaczor now anticipates that the company will earn ($0.51) per share for the quarter, up from their previous forecast of ($0.56). The consensus estimate for CVRx’s current full-year earnings is ($2.10) per share. William Blair also issued estimates for CVRx’s Q2 2024 earnings at ($0.48) EPS, Q3 2024 earnings at ($0.41) EPS, Q4 2024 earnings at ($0.43) EPS, FY2024 earnings at ($1.83) EPS, Q1 2025 earnings at ($0.39) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.37) EPS.

Other equities research analysts have also recently issued research reports about the company. Lake Street Capital increased their price target on CVRx from $18.00 to $21.00 in a research note on Wednesday, July 26th. Piper Sandler increased their target price on shares of CVRx from $20.00 to $21.00 in a research report on Wednesday, July 26th.

CVRx Stock Down 3.9 %

Shares of NASDAQ:CVRX opened at $18.24 on Thursday. The firm has a market cap of $379.68 million, a P/E ratio of -8.90 and a beta of 0.85. CVRx has a 12-month low of $6.57 and a 12-month high of $19.94. The business has a fifty day simple moving average of $14.82 and a 200 day simple moving average of $15.09. The company has a quick ratio of 12.52, a current ratio of 13.99 and a debt-to-equity ratio of 0.17.

CVRx (NASDAQ:CVRX) last released its quarterly earnings results on Thursday, October 26th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.14. CVRx had a negative net margin of 121.06% and a negative return on equity of 44.62%. The firm had revenue of $10.51 million during the quarter, compared to the consensus estimate of $9.83 million.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CVRX. Rhumbline Advisers grew its stake in CVRx by 8.9% during the third quarter. Rhumbline Advisers now owns 12,173 shares of the company’s stock worth $185,000 after purchasing an additional 999 shares during the period. HighMark Wealth Management LLC acquired a new stake in shares of CVRx during the 2nd quarter worth approximately $25,000. Tower Research Capital LLC TRC increased its stake in shares of CVRx by 320.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,092 shares of the company’s stock valued at $47,000 after acquiring an additional 2,357 shares in the last quarter. Advisor Group Holdings Inc. lifted its position in shares of CVRx by 71.1% during the 4th quarter. Advisor Group Holdings Inc. now owns 5,889 shares of the company’s stock valued at $109,000 after acquiring an additional 2,447 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in CVRx by 14.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 24,898 shares of the company’s stock worth $150,000 after acquiring an additional 3,102 shares in the last quarter. 56.50% of the stock is owned by institutional investors.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF.